Research & Development: Page 15
-
iStock via Getty Images
Patient groups have become a powerhouse in R&D. Here’s a look at their impact.
“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.
By Kelly Bilodeau • Oct. 25, 2023 -
Getty Images via Getty Images
Biotech SpotlightAn ‘inverse vaccine’ takes aim at autoimmune diseases
Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.
By Kelly Bilodeau • Oct. 23, 2023 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 100PharmaVoice 100s: Clinical trial gurus
Industry leaders adopting cutting-edge technologies and strategies to change the paradigm of clinical research.
By Meagan Parrish • Oct. 19, 2023 -
Stock via Getty Images
From the rainforest to Wall Street — Jaguar Health’s big play for revitalization
A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.
By Kelly Bilodeau • Oct. 17, 2023 -
Getty Images via Getty Images
Has the science of anti-aging caught up with the dream of a longer life?
Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.
By Kelly Bilodeau • Oct. 16, 2023 -
Permission granted by Alnylam/Yvonne Greenstreet
Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.
By Michael Gibney • Oct. 12, 2023 -
Gregor Fischer/DPA/Newscom
Deep DiveA decade later, biotech’s CRISPR revolution is still going strong
Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field’s pioneering scientists.
By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023 -
Stock via Getty Images
Q&A // Biotech SpotlightTo close the pediatric innovation gap, this biotech has to think differently
Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.
By Alexandra Pecci • Oct. 11, 2023 -
Permission granted by Mike Rea.
Q&A5 minutes with — IDEA Pharma’s Mike Rea
The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.
By Meagan Parrish • Oct. 11, 2023 -
Alexander Koerner / Stringer via Getty Images
Google bets on AI in the life sciences as ‘technology for a purpose’
A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.
By Alexandra Pecci • Oct. 10, 2023 -
Permission granted by Dr. Chia Soo
Research in space yields clues about boosting bone health on Earth
A study aimed at helping astronauts decrease bone loss could open the door to novel osteoporosis meds.
By Kelly Bilodeau • Oct. 10, 2023 -
Stock via Getty Images
Biotech SpotlightA biotech ‘tuning’ the genome for a potentially safer gene therapy
Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.
By Kelly Bilodeau • Oct. 9, 2023 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 100PharmaVoice 100s: Tech wizards
The leaders paving the way to pharma’s future with state-of-the-art digital solutions.
By Karissa Waddick • Oct. 9, 2023 -
Stock via Getty Images
Where have all the unicorns gone? A look at 4 billion-dollar biotechs
Not every unicorn company lives up to its $1 billion promise. Here are four worth watching.
By Alexandra Pecci • Oct. 3, 2023 -
Stock via Getty Images
The ALS therapy keeping the human pig heart transplant pumping
Eledon’s investigational ALS drug tegoprubart could also help prevent organ transplant rejections, the company says.
By Kelly Bilodeau • Oct. 2, 2023 -
Mario Tama / Getty via Getty Images
Q&AInside Bavarian Nordic’s late-stage stumbles — and drive to become a vaccine giant
Despite recent phase 3 setbacks in RSV and COVID-19, CEO Paul Chaplin sees a promising path forward in the travel vaccine market for the Danish biotech.
By Karissa Waddick • Sept. 27, 2023 -
iStock via Getty Images
Do humans have a place in pharma’s AI future?
From COTA’s large datasets and AI model assistants to a company guiding patients through cancer care, AI can help — but it’s a long way from human-free.
By Michael Gibney • Sept. 26, 2023 -
Stock via Getty Images
Q&A // First 90 DaysWhy Senda’s new chief medical officer says targeted delivery tech is like ‘science fiction’
The Flagship-backed biotech believes the secret to more precise drug delivery lies in the nanoparticles of plants and fungi.
By Alexandra Pecci • Sept. 26, 2023 -
Stock via Getty Images
Elderly exclusion: Clinical trials still fall short enrolling older adults
Despite high rates of disease in older populations, systemic issues are keeping them out of research studies.
By Kelly Bilodeau • Sept. 25, 2023 -
Stock via Getty Images
ProfileThree years after an FDA rejection, DBV sees a path for its peanut patch
Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.
By Karissa Waddick • Sept. 22, 2023 -
Illustration: Deena So Oteh for Industry Dive
The 2023 PharmaVoice 100
This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.
By Julia Himmel • Sept. 19, 2023 -
iStock via Getty Images
Endangered horseshoe crabs could lead the charge in pharma’s animal-free future
An effort to spare the species from blood collection is one of many ways the industry is turning away from animals for R&D.
By Kelly Bilodeau • Sept. 18, 2023 -
iStock via Getty Images
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.
By Michael Gibney • Sept. 15, 2023 -
saengsuriya13 via Getty Images
Q&AIn the renal space, innovation could tackle health disparities. But the system doesn’t reward it.
Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.
By Michael Gibney • Sept. 14, 2023 -
Stock via Getty Images
Catching up with 2022 PharmaVoice 100 honorees
Tapping into our growing community for expertise and inspiration.
By Meagan Parrish • Sept. 13, 2023
Previous
